<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32277872</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>26</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2468-1253</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The lancet. Gastroenterology &amp; hepatology</Title><ISOAbbreviation>Lancet Gastroenterol Hepatol</ISOAbbreviation></Journal><ArticleTitle>Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial.</ArticleTitle><Pagination><StartPage>658</StartPage><EndPage>666</EndPage><MedlinePgn>658-666</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S2468-1253(20)30056-X</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2468-1253(20)30056-X</ELocationID><Abstract><AbstractText Label="BACKGROUND">Bifidobacterium bifidum MIMBb75 is one of a few probiotic strains that have been shown to be effective in the treatment of irritable bowel syndrome (IBS) and its symptoms. Non-viable strains might have advantages over viable bacteria for product stability and standardisation, as well as for tolerability because safety concerns have been raised for specific patient groups who are susceptible to infection. We aimed to assess the efficacy of non-viable, heat-inactivated (HI) B bifidum MIMBb75 (SYN-HI-001) in the treatment of IBS and its symptoms.</AbstractText><AbstractText Label="METHODS">We did a double-blind, placebo-controlled trial in which patients with IBS were recruited from 20 study sites in Germany and randomly assigned to receive either two placebo capsules or two capsules with a combined total of 1&#x2008;&#xd7;&#x2008;10<sup>9</sup> non-viable B bifidum HI-MIMBb75 cells to be taken orally once a day for 8 weeks. Eligible patients were diagnosed with IBS according to Rome III criteria and had abdominal pain (&#x2265;4 on an 11-point numerical rating scale) on at least 2 days during a 2-week run-in phase. Patients with chronic inflammatory bowel diseases, systemic diseases, cancer, autoimmune diseases, with an intake of antipsychotic medications 3 months before study start, or with an intake of systemic corticosteroids within 1 month before study start were excluded. Randomisation was in a 1:1 ratio according to a computer-generated blocked list. Patients, investigators, clinical monitors, project managers, and statisticians were masked to the randomisation. The primary composite endpoint was the combination of at least 30% improvement of abdominal pain and adequate relief of overall IBS symptoms being fulfilled in at least 4 of 8 weeks during treatment. Analysis of the primary endpoint included all randomly assigned patients receiving at least one dose of study medication and who had no severe protocol violation. Safety analysis included all patients who had taken at least one dose of the study medication and was based on frequency and severity of adverse events, laboratory evaluation, and global assessment of tolerability. This trial is registered with the ISRCTN registry, ISRCTN14066467, and is completed: the results shown here represent the final analysis.</AbstractText><AbstractText Label="FINDINGS">Patients were screened between April 15, 2016, and Feb 3, 2017, and 443 patients were allocated to the placebo group (n=222) or the B bifidum HI-MIMBb75 group (n=221). The composite primary endpoint was reached by 74 (34%) of 221 patients in the B bifidum HI-MIMBb75 group compared with 43 (19%) of 222 in the placebo group (risk ratio 1&#xb7;7, 95% CI 1&#xb7;3-2&#xb7;4; p=0&#xb7;0007). No serious adverse events occurred in the B bifidum HI-MIMBb75 group; seven adverse events suspected to be related to the study product were reported in the B bifidum HI-MIMBb75 group as were eight in the placebo group. No deaths were reported in this study. The most common reported adverse event with a suspected relationship to the study product was abdominal pain, which was reported in two (&lt;1%) patients in the B bifidum HI-MIMBb75 group and one (&lt;1%) in the placebo group. Tolerability was rated as very good or good by 200 (91%) patients in the B bifidum HI-MIMBb75 group compared with 191 (86%) in the placebo group.</AbstractText><AbstractText Label="INTERPRETATION">This study shows that B bifidum HI-MIMBb75 substantially alleviates IBS and its symptoms in a real-life setting. These results indicate that specific beneficial bacterial effects are mediated independently of cell viability.</AbstractText><AbstractText Label="FUNDING">Synformulas.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Andresen</LastName><ForeName>Viola</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Israelitic Hospital, University of Hamburg Teaching Hospital, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gschossmann</LastName><ForeName>J&#xfc;rgen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital Forchheim, Forchheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Layer</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Israelitic Hospital, University of Hamburg Teaching Hospital, Hamburg, Germany. Electronic address: p.layer@ik-h.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Lancet Gastroenterol Hepatol</MedlineTA><NlmUniqueID>101690683</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Gastroenterol Hepatol. 2020 Jul;5(7):627-629. doi: 10.1016/S2468-1253(20)30079-0.</RefSource><PMID Version="1">32277873</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Gastroenterol Hepatol. 2020 Sep;5(9):797. doi: 10.1016/S2468-1253(20)30243-0.</RefSource><PMID Version="1">32818454</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Gastroenterol Hepatol. 2020 Sep;5(9):797-798. doi: 10.1016/S2468-1253(20)30239-9.</RefSource><PMID Version="1">32818455</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D015746" MajorTopicYN="N">Abdominal Pain</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069985" MajorTopicYN="N">Bifidobacterium bifidum</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007422" MajorTopicYN="N">Intestines</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010147" MajorTopicYN="N">Pain Measurement</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012449" MajorTopicYN="N">Safety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32277872</ArticleId><ArticleId IdType="doi">10.1016/S2468-1253(20)30056-X</ArticleId><ArticleId IdType="pii">S2468-1253(20)30056-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32635661</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2072-6643</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>Jul</Month><Day>05</Day></PubDate></JournalIssue><Title>Nutrients</Title><ISOAbbreviation>Nutrients</ISOAbbreviation></Journal><ArticleTitle>The Effectiveness of Synbiotic Preparation Containing <i>Lactobacillus</i> and <i>Bifidobacterium</i> Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant Irritable Bowel Syndrome-A Randomized Double-Blind, Placebo-Controlled Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1999</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/nu12071999</ELocationID><Abstract><AbstractText>The purpose of the randomized double-blind placebo-controlled trial was to assess the effectiveness of synbiotic preparation containing probiotic <i>Lactobacillus rhamnosus</i> FloraActive&#x2122; 19070-2, <i>Lactobacillus acidophilus</i> DSMZ 32418, <i>Bifidobacterium lactis</i> DSMZ 32269, <i>Bifidobacterium longum</i> DSMZ 32946, <i>Bifidobacterium bifidum</i> DSMZ 32403 and fructooligosaccharides in adult patients with diarrhea-dominant IBS (IBS-D). The study included eighty patients with moderate and severe IBS-D who were randomized to receive synbiotics or placebo for eight weeks. Finally, a total of sixty-eight patients finished the study. The primary endpoints included the assessment of the symptoms' severity with IBS symptom severity scale (IBS-SSS), an improvement of IBS global symptoms with Global Improvement Scale (IBS-GIS) and adequate relief of symptoms after four and eight weeks of therapy. Secondary endpoints, which were collected by telephone interviewers three times a week included the assessment of individual IBS symptoms and adverse events. Synbiotic treatment in comparison to placebo significantly improved IBS-GIS (<i>p</i> = 0.043), and IBS-SSS score inducing a decrease in the total IBS-SSS (<i>p</i> = 0.042) and in domain-specific scores related to flatulence (<i>p</i> = 0.028) and bowel habit (<i>p</i> = 0.028) after four and eight weeks. Patients treated with synbiotics reported in weekly observations a significant amelioration in a feeling of incomplete bowel movements, flatulence, pain, stool pressure and diarrheal stools compared to those receiving placebo. There were no differences in adverse events between both groups. Concluding, the multi-strain synbiotic preparation was associated with a significant improvement in symptoms in IBS-D patients and was well-tolerated. These results suggest that the use of synbiotics offers a benefit for IBS-D patients. [Clinicaltrials.gov NCT04206410 registered 20 December 2019].</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Skrzyd&#x142;o-Radoma&#x144;ska</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Medical University of Lublin, Jaczewskiego 8, 20-950 Lublin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prozorow-Kr&#xf3;l</LastName><ForeName>Beata</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Medical University of Lublin, Jaczewskiego 8, 20-950 Lublin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cicho&#x17c;-Lach</LastName><ForeName>Halina</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Medical University of Lublin, Jaczewskiego 8, 20-950 Lublin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Majsiak</LastName><ForeName>Emilia</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-3638-9292</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Cardinal Stefan Wyszynski University, W&#xf3;ycickiego 1/3, 01-938 Warszaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bier&#x142;a</LastName><ForeName>Joanna B</ForeName><Initials>JB</Initials><Identifier Source="ORCID">0000-0002-5772-5091</Identifier><AffiliationInfo><Affiliation>Department of Pathology, The Children Memorial Health Institute, Aleja Dzieci Polskich 20, 04-730 Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kosikowski</LastName><ForeName>Wojciech</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Out-Patient Clinic, Konopnica 96L, 21-030 Motycz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szczerbi&#x144;ski</LastName><ForeName>Mariusz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Medical University of Lublin, Jaczewskiego 8, 20-950 Lublin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gantzel</LastName><ForeName>Jesper</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1897-0841</Identifier><AffiliationInfo><Affiliation>Biocare Copenhagen, Ole Maaloes Vej 3, DK-2200 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cukrowska</LastName><ForeName>Bo&#x17c;ena</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pathology, The Children Memorial Health Institute, Aleja Dzieci Polskich 20, 04-730 Warsaw, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04206410</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>6/KBE/2018</GrantID><Agency>Biocare, Copenhagen, Denmark</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Nutrients</MedlineTA><NlmUniqueID>101521595</NlmUniqueID><ISSNLinking>2072-6643</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009844">Oligosaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C116580">fructooligosaccharide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069982" MajorTopicYN="N">Bifidobacterium animalis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069985" MajorTopicYN="N">Bifidobacterium bifidum</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069978" MajorTopicYN="N">Bifidobacterium longum</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003672" MajorTopicYN="N">Defecation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005243" MajorTopicYN="N">Feces</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005414" MajorTopicYN="N">Flatulence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007779" MajorTopicYN="N">Lactobacillus acidophilus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052201" MajorTopicYN="N">Lacticaseibacillus rhamnosus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009844" MajorTopicYN="N">Oligosaccharides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058616" MajorTopicYN="N">Synbiotics</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bifidobacterium</Keyword><Keyword MajorTopicYN="N">Lactobacillus</Keyword><Keyword MajorTopicYN="N">irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">prebiotics</Keyword><Keyword MajorTopicYN="N">probiotics</Keyword><Keyword MajorTopicYN="N">short chain fructooligosaccharides</Keyword><Keyword MajorTopicYN="N">synbiotics</Keyword></KeywordList><CoiStatement>B.C. has served as a speaker for Nutricia, Danone, Bayer, Apotex, Polpharma, and Mead Johnson. J.G. is the co-founder of Biocare Copenhagen, a company acquired by DSM Nutritional Products in 2017, but was not involved in conducting the study and data analyses. Other authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32635661</ArticleId><ArticleId IdType="pmc">PMC7400954</ArticleId><ArticleId IdType="doi">10.3390/nu12071999</ArticleId><ArticleId IdType="pii">nu12071999</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ford A.C., Lacy B.E., Talley N.J. Irritable bowel syndrome. N. Engl. J. Med. 2017;376:2566&#x2013;2578. doi: 10.1056/NEJMra1607547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1607547</ArticleId><ArticleId IdType="pubmed">28657875</ArticleId></ArticleIdList></Reference><Reference><Citation>Canavan C., West J., Card T. The epidemiology of irritable bowel syndrome. Clin. Epidemiol. 2014;6:71&#x2013;80. doi: 10.1007/s40273-015-0339-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40273-015-0339-y</ArticleId><ArticleId IdType="pmc">PMC3921083</ArticleId><ArticleId IdType="pubmed">24523597</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiegel B.M., Farid M., Esrailian E., Talley J., Chang L. Is Irritable bowel syndrome a diagnosis of exclusion? A survey of primary care providers, gastroenterologists, and IBS experts. Am. J. Gastroenterol. 2010;105:848&#x2013;858. doi: 10.1038/ajg.2010.47.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2010.47</ArticleId><ArticleId IdType="pmc">PMC2887205</ArticleId><ArticleId IdType="pubmed">20197761</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattarai Y., Pedrogo D.A.M., Kashyap P.C. Irritable bowel syndrome: A gut microbiota-related disorder? Am. J. Physiol.-Gastrointest. Liver Physiol. 2016;312:G52&#x2013;G62. doi: 10.1152/ajpgi.00338.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.00338.2016</ArticleId><ArticleId IdType="pmc">PMC5283907</ArticleId><ArticleId IdType="pubmed">27881403</ArticleId></ArticleIdList></Reference><Reference><Citation>Distrutti E., Monaldi L., Ricci P., Fiorucci S. Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. World J. Gastroenterol. 2016;22:2219&#x2013;2241. doi: 10.3748/wjg.v22.i7.2219.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v22.i7.2219</ArticleId><ArticleId IdType="pmc">PMC4734998</ArticleId><ArticleId IdType="pubmed">26900286</ArticleId></ArticleIdList></Reference><Reference><Citation>Mari A., Baker F.A., Mahamid M., Sbeit W., Khoury T. The Evolving role of gut microbiota in the management of irritable bowel syndrome: An overview of the current knowledge. J. Clin. Med. 2020;9:685. doi: 10.3390/jcm9030685.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9030685</ArticleId><ArticleId IdType="pmc">PMC7141230</ArticleId><ArticleId IdType="pubmed">32143424</ArticleId></ArticleIdList></Reference><Reference><Citation>Vivinus-N&#xe9;bot M., Frin-Mathy G., Bzioueche H., Dainese R., Bernard G., Anty R., Filippi J., Saint-Paul M.C., Tulic M.K., Verhasselt V., et al. Functional bowel symptoms in quiescent inflammatory bowel diseases: Role of epithelial barrier disruption and low-grade inflammation. Gut. 2013;63:744&#x2013;752. doi: 10.1136/gutjnl-2012-304066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2012-304066</ArticleId><ArticleId IdType="pubmed">23878165</ArticleId></ArticleIdList></Reference><Reference><Citation>Pusceddu M.M., Gareau M.G. Visceral pain: Gut microbiota, a new hope? J. Biomed. Sci. 2018;25:73. doi: 10.1186/s12929-018-0476-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-018-0476-7</ArticleId><ArticleId IdType="pmc">PMC6182804</ArticleId><ArticleId IdType="pubmed">30309367</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou S., Gillilland M.G., Wu X., Leelasinjaroen P., Zhang G., Zhou H., Ye B., Lu Y., Owyang C. FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction. J. Clin. Investig. 2017;128:267&#x2013;280. doi: 10.1172/JCI92390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI92390</ArticleId><ArticleId IdType="pmc">PMC5749529</ArticleId><ArticleId IdType="pubmed">29202473</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H.R., Pimentel M. Bacteria and irritable bowel syndrome: The evidence for small intestinal bacterial overgrowth. Curr. Gastroenterol. Rep. 2006;8:305&#x2013;311. doi: 10.1007/s11894-006-0051-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11894-006-0051-3</ArticleId><ArticleId IdType="pubmed">16836942</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll I.M., Ringel-Kulka T., Siddle J.P., Ringel Y. Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol. Motil. 2012;24:521&#x2013;530.e248. doi: 10.1111/j.1365-2982.2012.01891.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2012.01891.x</ArticleId><ArticleId IdType="pmc">PMC3975596</ArticleId><ArticleId IdType="pubmed">22339879</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll I.M., Ringel-Kulka T., Keku T.O., Chang Y.-H., Packey C.D., Sartor R.B., Ringel Y. Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am. J. Physiol.-Gastrointest. Liver Physiol. 2011;301:G799&#x2013;G807. doi: 10.1152/ajpgi.00154.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.00154.2011</ArticleId><ArticleId IdType="pmc">PMC3220325</ArticleId><ArticleId IdType="pubmed">21737778</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerckhoffs A.P.M., Samsom M., van der Rest M.E., de Vogel J., Knol J., Ben-Amor K., Akkermans L.M. Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J. Gastroenterol. 2009;15:2887&#x2013;2892. doi: 10.3748/wjg.15.2887.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.15.2887</ArticleId><ArticleId IdType="pmc">PMC2699007</ArticleId><ArticleId IdType="pubmed">19533811</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozuelo M., Panda S., Santiago A., Mendez S., Accarino A., Santos J., Guarner F., Azpiroz F., Manichanh C. Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome. Sci. Rep. 2015;5:12693. doi: 10.1038/srep12693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep12693</ArticleId><ArticleId IdType="pmc">PMC4523847</ArticleId><ArticleId IdType="pubmed">26239401</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill C., Guarner F., Reid G., Gibson G.R., Merenstein D.J., Pot B., Morelli L., Canani R.B., Flint H.J., Salminen S., et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 2014;11:506&#x2013;514. doi: 10.1038/nrgastro.2014.66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2014.66</ArticleId><ArticleId IdType="pubmed">24912386</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson G.R., Hutkins R., Sanders M.E., Prescott S.L., Reimer R.A., Salminen S.J., Scott K., Stanton C., Swanson K.S., Cani P.D., et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat. Rev. Gastroenterol. Hepatol. 2017;14:491&#x2013;502. doi: 10.1038/nrgastro.2017.75.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2017.75</ArticleId><ArticleId IdType="pubmed">28611480</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B., Liang L., Deng H., Guo J., Shu H., Zhang L. Efficacy and Safety of Probiotics in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. Front. Pharmacol. 2020;11:332. doi: 10.3389/fphar.2020.00332.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.00332</ArticleId><ArticleId IdType="pmc">PMC7147251</ArticleId><ArticleId IdType="pubmed">32317962</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford A.C., Harris L.A., Lacy B.E., Quigley E., Moayyedi P. Systematic review with meta-analysis: The efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment. Pharmacol. Ther. 2018;48:1044&#x2013;1060. doi: 10.1111/apt.15001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15001</ArticleId><ArticleId IdType="pubmed">30294792</ArticleId></ArticleIdList></Reference><Reference><Citation>Asha M.Z., Khalil S.F.H. Efficacy and safety of probiotics, prebiotics and synbiotics in the treatment of irritable bowel syndrome: A systematic review and meta-analysis. Sultan Qaboos Univ. Med. J. 2020;20:e13&#x2013;e24. doi: 10.18295/squmj.2020.20.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.18295/squmj.2020.20.01.003</ArticleId><ArticleId IdType="pmc">PMC7065695</ArticleId><ArticleId IdType="pubmed">32190365</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Li L., Guo C., Mu D., Feng B., Zuo X., Li Y. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: A meta-analysis. BMC Gastroenterol. 2016;16:62. doi: 10.1186/s12876-016-0470-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12876-016-0470-z</ArticleId><ArticleId IdType="pmc">PMC4907258</ArticleId><ArticleId IdType="pubmed">27296254</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuchiya J., Barreto R., Okura R., Kawakita S., Fesce E., Marotta F. Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin. J. Dig. Dis. 2004;5:169&#x2013;174. doi: 10.1111/j.1443-9573.2004.00176.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1443-9573.2004.00176.x</ArticleId><ArticleId IdType="pubmed">15612887</ArticleId></ArticleIdList></Reference><Reference><Citation>Min Y.W., Park S.U., Jang Y.S., Kim Y.-H., Rhee P.-L., Ko S.H., Joo N., Kim S.I., Kim C.-H., Chang D.K. Effect of composite yogurt enriched with acacia fiber and Bifidobacterium lactis. World J. Gastroenterol. 2012;18:4563&#x2013;4569. doi: 10.3748/wjg.v18.i33.4563.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v18.i33.4563</ArticleId><ArticleId IdType="pmc">PMC3435782</ArticleId><ArticleId IdType="pubmed">22969230</ArticleId></ArticleIdList></Reference><Reference><Citation>A Drossman U., Dumitrascu D.L. Rome III: New standard for functional gastrointestinal disorders. J. Gastrointest. Liver Dis. 2006;15:237&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pubmed">17013448</ArticleId></ArticleIdList></Reference><Reference><Citation>Riegler G., Esposito I. Bristol scale stool form. A still valid help in medical practice and clinical research. Tech. Coloproctology. 2001;5:163&#x2013;164. doi: 10.1007/s101510100019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s101510100019</ArticleId><ArticleId IdType="pubmed">11875684</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis C.Y., Morris J., Whorwell P. The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress. Aliment. Pharmacol. Ther. 1997;11:395&#x2013;402. doi: 10.1046/j.1365-2036.1997.142318000.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.1997.142318000.x</ArticleId><ArticleId IdType="pubmed">9146781</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagala R., Routray C. Clinical case study&#x2014;Multispecies probiotic supplement minimizes symptoms of irritable bowel syndrome. US Gastroenterol. Hepatol. Rev. 2011;7:36&#x2013;37.</Citation></Reference><Reference><Citation>Gerasimov S., Gantzel J., Dementieva N., Schevchenko O., Tsitsura O., Guta N., Bobyk V., Kaprus V. Role of Lactobacillus rhamnosus (FloraActive&#x2122;) 19070-2 and Lactobacillus reuteri (FloraActive&#x2122;) 12246 in Infant Colic: A Randomized Dietary Study. Nutrients. 2018;10:1975. doi: 10.3390/nu10121975.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu10121975</ArticleId><ArticleId IdType="pmc">PMC6315585</ArticleId><ArticleId IdType="pubmed">30551654</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang D., Longgui N., Guoqiang X. Efficacy of different probiotic protocols in irritable bowel syndrome: A network meta-analysis. Medicine. 2019;98:e16068. doi: 10.1097/MD.0000000000016068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000016068</ArticleId><ArticleId IdType="pmc">PMC6635271</ArticleId><ArticleId IdType="pubmed">31277101</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon S., Ameen V., Bagby B., Shahan B., Jhingran P., Carter E. Validation of irritable bowel syndrome Global Improvement Scale: An integrated symptom end point for assessing treatment efficacy. Dig. Dis. Sci. 2003;48:1317&#x2013;1323. doi: 10.1023/A:1024159226274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1024159226274</ArticleId><ArticleId IdType="pubmed">12870789</ArticleId></ArticleIdList></Reference><Reference><Citation>Gracie D.J., Ford A.C. Symbiotics in irritable bowel syndrome&#x2014;Better than probiotics alone? Curr. Opin. Clin. Nutr. Metab. Care. 2015;18:485&#x2013;489. doi: 10.1097/MCO.0000000000000199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCO.0000000000000199</ArticleId><ArticleId IdType="pubmed">26107141</ArticleId></ArticleIdList></Reference><Reference><Citation>Shavakhi A., Minakari M., Farzamnia S., Peykar M.S., Taghipour G., Tayebi A., Hashemi H., Shavakhi S. The effects of multi-strain probiotic compound on symptoms and quality-of-life in patients with irritable bowel syndrome: A randomized placebo-controlled trial. Adv. Biomed. Res. 2014;3:139. doi: 10.4103/2277-9175.135157.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2277-9175.135157</ArticleId><ArticleId IdType="pmc">PMC4139977</ArticleId><ArticleId IdType="pubmed">25161987</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappello C., Tremolaterra F., Pascariello A., Ciacci C., Iovino P. A randomised clinical trial (RCT) of a symbiotic mixture in patients with irritable bowel syndrome (IBS): Effects on symptoms, colonic transit and quality of life. Int. J. Colorectal Dis. 2012;28:349&#x2013;358. doi: 10.1007/s00384-012-1552-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-012-1552-1</ArticleId><ArticleId IdType="pmc">PMC3587687</ArticleId><ArticleId IdType="pubmed">22885882</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogha M., Esfahani M.Z., Zargarzadeh A.H. The efficacy of a synbiotic containing Bacillus Coagulans in treatment of irritable bowel syndrome: A randomized placebo-controlled trial. Gastroenterol. Hepatol. Bed Bench. 2014;7:156&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4129566</ArticleId><ArticleId IdType="pubmed">25120896</ArticleId></ArticleIdList></Reference><Reference><Citation>Guarino M.P.L., Altomare A., Emerenziani S., Di Rosa C., Ribolsi M., Balestrieri P., Iovino P., Rocchi G., Cicala M. Mechanisms of action of prebiotics and their effects on gastro-intestinal disorders in adults. Nutrients. 2020;12:1037. doi: 10.3390/nu12041037.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12041037</ArticleId><ArticleId IdType="pmc">PMC7231265</ArticleId><ArticleId IdType="pubmed">32283802</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Perkins A.C., Spiller R.C. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am. J. Gastroenterol. 2006;101:1288&#x2013;1294. doi: 10.1111/j.1572-0241.2006.00672.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2006.00672.x</ArticleId><ArticleId IdType="pubmed">16771951</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouhnik Y., Raskine L., Simoneau G., Paineau D., Bornet F. The capacity of short-chain fructo-oligosaccharides to stimulate faecal bifidobacteria: A dose-response relationship study in healthy humans. Nutr. J. 2006;5:8. doi: 10.1186/1475-2891-5-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1475-2891-5-8</ArticleId><ArticleId IdType="pmc">PMC1448190</ArticleId><ArticleId IdType="pubmed">16569219</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukahara T., Iwasaki Y., Nakayama K., Ushida K. Stimulation of butyrate production in the large intestine of weaning piglets by dietary fructooligosaccharides and its influence on the histological variables of the large intestinal mucosa. J. Nutr. Sci. Vitaminol. 2003;49:414&#x2013;421. doi: 10.3177/jnsv.49.414.</Citation><ArticleIdList><ArticleId IdType="doi">10.3177/jnsv.49.414</ArticleId><ArticleId IdType="pubmed">14974732</ArticleId></ArticleIdList></Reference><Reference><Citation>Paineau D., Payen F., Panserieu S., Coulombier G., Sobaszek A., Lartigau I., Brabet M., Galmiche J.-P., Tripodi D., Sacher-Huvelin S., et al. The effects of regular consumption of short-chain fructo-oligosaccharides on digestive comfort of subjects with minor functional bowel disorders. Br. J. Nutr. 2008;99:311&#x2013;318. doi: 10.1017/S000711450779894X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S000711450779894X</ArticleId><ArticleId IdType="pubmed">17697398</ArticleId></ArticleIdList></Reference><Reference><Citation>Azpiroz F., DuBray C., Bernalier-Donadille A., Cardot J.M., Accarino A., Serra J., Wagner A., Respondek F., Dapoigny M. Effects of scFOS on the composition of fecal microbiota and anxiety in patients with irritable bowel syndrome: A randomized, double blind, placebo controlled study. Neurogastroenterol. Motil. 2016;29:e12911. doi: 10.1111/nmo.12911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.12911</ArticleId><ArticleId IdType="pubmed">27477485</ArticleId></ArticleIdList></Reference><Reference><Citation>Basturk A., Artan R., Y&#x131;lmaz A. Efficacy of synbiotic, probiotic, and prebiotic treatments for irritable bowel syndrome in children: A randomized controlled trial. Turk. J. Gastroenterol. 2020;27:439&#x2013;443. doi: 10.5152/tjg.2016.16301.</Citation><ArticleIdList><ArticleId IdType="doi">10.5152/tjg.2016.16301</ArticleId><ArticleId IdType="pubmed">27782892</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahrudin M.F., Rani R.A., Tamil A.M., Mokhtar N.M., Ali R.A.R. Effectiveness of sterilized symbiotic drink containing Lactobacillus helveticus comparable to probiotic alone in patients with constipation-predominant irritable bowel syndrome. Dig. Dis. Sci. 2019;65:541&#x2013;549. doi: 10.1007/s10620-019-05695-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-019-05695-3</ArticleId><ArticleId IdType="pmc">PMC6995448</ArticleId><ArticleId IdType="pubmed">31209720</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21418261</PMID><DateCompleted><Year>2011</Year><Month>11</Month><Day>28</Day></DateCompleted><DateRevised><Year>2011</Year><Month>04</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2036</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>10</Issue><PubDate><Year>2011</Year><Month>May</Month></PubDate></JournalIssue><Title>Alimentary pharmacology &amp; therapeutics</Title><ISOAbbreviation>Aliment Pharmacol Ther</ISOAbbreviation></Journal><ArticleTitle>Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study.</ArticleTitle><Pagination><StartPage>1123</StartPage><EndPage>1132</EndPage><MedlinePgn>1123-32</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1365-2036.2011.04633.x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Recent research suggests that an imbalance of the intestinal microbiota and a dysfunctional intestinal barrier might trigger irritable bowel syndrome (IBS). As probiotics have been reported to restore the intestinal microbiota and the gut barrier, the therapeutic potential of probiotics within IBS became of strong interest.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To assess the efficacy of Bifidobacterium bifidum MIMBb75 in IBS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 122 patients were randomised to receive either placebo (N=62) or MIMBb75 (N=60) once a day for 4 weeks. The severity of IBS symptoms was recorded daily on a 7-point Likert scale.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">MIMBb75 significantly reduced the global assessment of IBS symptoms by -0.88 points (95% CI: -1.07; -0.69) when compared with only -0.16 (95% CI: -0.32; 0.00) points in the placebo group (P&lt;0.0001). MIMBb75 also significantly improved the IBS symptoms pain/discomfort, distension/bloating, urgency and digestive disorder. The evaluation of the SF12 sum scores showed a significant gain in quality of life within the bifidobacteria group. Furthermore, adequate relief was reported by 47% of the patients in the bifidobacteria and only by 11% of the patients in the placebo group (P&lt;0.0001). Overall responder rates were 57% in the bifidobacteria group but only 21% in the placebo group (P=0.0001). MIMBb75 was well tolerated and adverse events were not different from placebo.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Bifidobacterium bifidum MIMBb75 effectively alleviates global IBS and improves IBS symptoms simultaneously with an improvement of quality of life. Considering the high efficacy of MIMBb75 in IBS along with the good side-effect profile, MIMBb75 is a promising candidate for IBS therapy.</AbstractText><CopyrightInformation>&#xa9; 2011 Blackwell Publishing Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guglielmetti</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Food Science and Microbiology, Universit&#xe0; degli Studi di Milano,Via Celoria 2, Milan, Italy. simone.guglielmetti@unimi.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mora</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Gschwender</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Popp</LastName><ForeName>K</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>03</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aliment Pharmacol Ther</MedlineTA><NlmUniqueID>8707234</NlmUniqueID><ISSNLinking>0269-2813</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Aliment Pharmacol Ther. 2011 Jul;34(1):100-1; author reply 101. doi: 10.1111/j.1365-2036.2011.04671.x.</RefSource><PMID Version="1">21631550</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001644" MajorTopicYN="Y">Bifidobacterium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007422" MajorTopicYN="N">Intestines</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>12</Month><Day>13</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21418261</ArticleId><ArticleId IdType="doi">10.1111/j.1365-2036.2011.04633.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18785988</PMID><DateCompleted><Year>2011</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2036</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>1</Issue><PubDate><Year>2009</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Alimentary pharmacology &amp; therapeutics</Title><ISOAbbreviation>Aliment Pharmacol Ther</ISOAbbreviation></Journal><ArticleTitle>Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study.</ArticleTitle><Pagination><StartPage>97</StartPage><EndPage>103</EndPage><MedlinePgn>97-103</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1365-2036.2008.03848.x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The efficacy of probiotics in alleviating the symptoms of irritable bowel syndrome (IBS) appears to be both strain- and dose-related.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To investigate the effect of LAB4, a multistrain probiotic preparation on symptoms of IBS. This probiotic preparation has not previously been assessed in IBS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Fifty-two participants with IBS, as defined by the Rome II criteria, participated in this double blind, randomized, placebo-controlled study. Participants were randomized to receive either a probiotic preparation comprising two strains of Lactobacillus acidophilus CUL60 (NCIMB 30157) and CUL21 (NCIMB 30156), Bifidobacterium lactis CUL34 (NCIMB 30172) and Bifidobacterium bifidum CUL20 (NCIMB 30153) at a total of 2.5 &#xd7; 10(10) cfu/capsule or a placebo for 8 weeks. Participants reported their IBS symptoms using a questionnaire fortnightly during the intervention and at 2 weeks post-intervention.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A significantly greater improvement in the Symptom Severity Score of IBS and in scores for quality of life, days with pain and satisfaction with bowel habit was observed over the 8-week intervention period in the volunteers receiving the probiotic preparation than in the placebo group.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">LAB4 multistrain probiotic supplement may benefit subjects with IBS.</AbstractText><CopyrightInformation>&#xa9; 2008 The Authors. Journal compilation &#xa9; 2008 Blackwell Publishing Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>E A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Human Nutrition Unit, School of Medicine, The University of Sheffield, Sheffield, UK. e.a.williams@sheffield.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stimpson</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Plummer</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Garaiova</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Barker</LastName><ForeName>M E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Corfe</LastName><ForeName>B M</ForeName><Initials>BM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aliment Pharmacol Ther</MedlineTA><NlmUniqueID>8707234</NlmUniqueID><ISSNLinking>0269-2813</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001644" MajorTopicYN="N">Bifidobacterium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003672" MajorTopicYN="N">Defecation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007779" MajorTopicYN="N">Lactobacillus acidophilus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>9</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>9</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18785988</ArticleId><ArticleId IdType="doi">10.1111/j.1365-2036.2008.03848.x</ArticleId><ArticleId IdType="pii">APT3848</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>